EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Resmed Inc (RMD) fair value: what the stock is really worth

We calculate from audited financials what Resmed Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · AU · ISIN AU000000RMD6

RI Resmed Inc logo Broad data Sep 17, 2026

Resmed Inc

RMD · AU

Quality WatchlistQuality growthA strong company, but the current price is close to Fair Value.

·Fair value A$35.09 · Fairly valued (+10%)
✓Quality 77/100
✓Healthy Growth (revenue 5y +11.7 %/yr)
✓Highly profitable · 27.4% net margin (TTM)
✓Low debt · generates free cash flow
·1.06% dividend yield
✓Ranks above peers (9/15)
✓Wide moat 88/100
!Insider activity 45/100
!The models disagree: range A$24.56 to A$74.73
!Weak on dividend: 21 out of 100
Watch Resmed Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$44.81 A$20.92 Fair Value A$35.09 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 17, 2026.

How to read this chart

60‑month range A$20.92 – A$44.81 · fair‑value band A$24.56 – A$74.73 · the A$31.87 price screens below the A$35.09 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 17, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software.

Show more

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Stock analysis

Resmed Inc (RMD) currently trades at A$31.87, while our model-based Fair Value estimate is A$35.09, implying the stock looks roughly 9.2% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of A$25.65 per share, and 1 of the 24 models we run sit above the A$31.87 price.

Bear case: the Economic Profit group reads lowest at A$8.61, and 23 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: A$24.56 (bear) to A$74.73 (bull), the price of A$31.87 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 77/100 (high quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Resmed Inc reported revenue of $5.1B in FY2025 versus $3.2B in FY2021, a compound +12.6%/yr. Reported net income was $1.4B in FY2025, compounding +31.1%/yr from FY2021.

Key figures

Market cap A$47.0B (≈ $33.5B) · P/E ratio 22.0 · P/S ratio 5.98 · EPS (TTM) A$1.45 · Dividend yield 1.1% · Net margin 27.2% · Return on equity 25.3% · Return on assets (EBIT) 19.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (medium confidence).

What moves the price

The share trades about 29% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −46% fair-value upside, at 10%, RMD screens cheaper than that median.

Fair Value models

Bear A$24.56 Fair Value A$35.09 Bull A$74.73
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (A$1.16 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF A$15.94 A$30.52 A$57.47 76
Growth DCF A$15.65 A$28.54 A$51.34 75
EPV A$9.63 A$11.17 A$12.52 74
All 24 models by family
DCF Models
FCF DCF A$15.94 A$30.52 A$57.47 76
Owner Earnings A$14.85 A$28.44 A$53.49 73
5Y Revenue Exit A$10.36 A$17.38 A$26.93 71
5Y EBITDA Exit A$14.21 A$25.65 A$40.38 73
5Y P/E Exit A$15.52 A$28.48 A$43.82 69
10Y Revenue Exit A$11.79 A$19.27 A$30.95 65
10Y EBITDA Exit A$14.66 A$25.49 A$42.69 66
10Y P/E Exit A$15.55 A$27.61 A$45.69 62
Earnings-Based
Graham-Dodd A$6.57 A$35.03 A$48.52 63
Lynch FV A$9.67 A$13.81 A$17.95 61
PEG = 1.0 A$9.67 A$13.81 A$17.95 57
EPV A$9.63 A$11.17 A$12.52 74
Multiples
P/E Multiple A$15.93 A$21.24 A$26.56 63
P/S Multiple A$9.31 A$12.42 A$15.52 58
P/B Multiple A$12.31 A$16.42 A$20.52 55
EV/EBIT A$15.19 A$20.13 A$25.07 66
EV/EBITDA A$14.29 A$18.92 A$23.56 67
EV/Revenue A$7.83 A$11.02 A$14.22 54
Asset-Based
NCAV (Graham) A$2.06 A$2.76 A$4.11 54
Growth DCF
Growth DCF A$15.65 A$28.54 A$51.34 75
Rev-Margin DCF A$10.36 A$17.25 A$26.57 71
Economic Profit
Residual Income A$6.41 A$8.61 A$43.76 64
ROIC Compounder A$11.11 A$14.95 A$19.91 71
Growth Earnings
Growth-Adj P/E A$14.61 A$20.87 A$27.13 67

Open the full fair value analysis →

Notify me when RMD reaches fair value

Put RMD on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 77/100

Of which business quality 76 · Market factors (momentum, volatility) 45

Profitability 77
Margins and returns on capital today
Quality Growth 64
Are margins and returns improving?
Cashflow 87
Earnings quality: real cash, not paper profit
Fin. Strength 89
Balance sheet, leverage, solvency risk
Investment 38
Disciplined investing over empire-building
Low Volatility 72
Calm price path (market factor)
Momentum 40
Price trend over the last 3–12 months (market factor)
52W Momentum 21
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+9.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.7%
Revenue growth 32 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.5%
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+18.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+17.2%
Dividend (yield on the price)1.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.24% vs 14%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.27% → 33%
2025 sits 56% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Growth Forecast

A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+12.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.8%
Yearly sales growth analysts expect, extended to five years.
Forecast 2026 (sales)+8.9%
Forecast 2027 (sales)+8.9%
Projected 2028 (sales)+8.0%
Projected 2029 (sales)+7.2%
Projected 2030 (sales)+6.3%

Watch RMD, get fair value alerts →

Compare Resmed Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 200 stocks

Beats the industry median on 9/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 77 · Top 25%
Fair Value upside −17% · Below median
Profitability
Return on equity (TTM) 25% · Top 25%
Return on assets 15% · Top 25%
Net margin (TTM) 27% · Top 25%
Operating margin (TTM) 35% · Top 25%
Growth and dividend
Revenue growth 11% · Above median
Dividend yield (TTM) 1.1% · Below median
Balance sheet
Debt / equity 0.11× · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 22.0× · Cheaper than median
P/B 4.86× · Priciest 25%
P/S (TTM) 5.24× · Priciest 25%
P/FCF 17.6× · Pricier than median
EV/EBITDA 13.4× · Cheaper than median
PEG 1.16× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)47 · sector 15
FUTURE (revenue growth)54 · sector 27
PAST (return on equity)100 · sector 25
HEALTH (low debt)95 · sector 96
DIVIDEND (yield)21 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $377.16 $350.02 −7%
EssilorLuxottica Société anonyme EL €145.10 €159.61 +10%
Medline Inc MDLN $32.11 $11.65 −64%
Becton, Dickinson and Company BDX $185.92 $100.46 −46%
Alcon Inc ALC $67.76 $39.78 −41%
West Pharmaceutical Services, Inc WST $362.01 $137.28 −62%
Sartorius Stedim Biotech S.A DIM €196.10 €48.88 −75%
Straumann Holding STMN CHF 94.66 CHF 45.50 −52%
Sartorius Aktiengesellschaft SRT3 €248.70 €42.05 −83%
Coloplast A/S COLOB kr 420.10 kr 382.22 −9%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Resmed Inc · Fair Value
A$35.09 +9%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Resmed Inc Fair Value". https://www.fairvalue-calculator.com/stock/RMD

Frequently asked questions

Is Resmed Inc (RMD) overvalued or undervalued?
As of Sep 17, 2026, our model estimates a fair value of A$35.09 versus a price of A$31.87, about +10% upside (undervalued).
What is the fair value of RMD?
Our model-based fair value for Resmed Inc is A$35.09 (as of Sep 17, 2026), built from audited fundamentals. The current price: A$31.87.
What is the quality score of RMD?
Resmed Inc has a Quality Score of 77/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Resmed Inc (RMD)?
Our model-based price target is the fair value of A$35.09 (as of Sep 17, 2026) from 24 valuation models. Cautious scenario A$24.56, optimistic scenario A$74.73. It is a calculation from audited fundamentals, not an analyst target.
What is the Resmed Inc stock forecast for 2026?
Our models put fair value at A$35.09, about +10% upside versus a price of A$31.87 (undervalued). Cautious scenario A$24.56, optimistic scenario A$74.73. The calculation is refreshed regularly with new filings.
What is the revenue of Resmed Inc (RMD)?
Resmed Inc reported trailing-twelve-month revenue of about A$5.5B (latest available figure, as of Sep 17, 2026).
Does Resmed Inc pay a dividend?
Resmed Inc currently shows a dividend yield of about 1.06% relative to its recent price (as of Sep 17, 2026).
What growth is priced into Resmed Inc (RMD)?
For today's price to be fair in a discounted-cash-flow model, Resmed Inc would have to grow free cash flow by +12.4 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.7 % per year. As of Sep 17, 2026.
What discount rate (WACC) does the fair value of RMD use?
Our models discount Resmed Inc at 8.5 %: a base by market capitalisation (large), damped by beta 0.78, country premium for Australia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Resmed Inc that is +12.4 % per year a year over ten years, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Resmed Inc (RMD) delivered so far?
Over the past 5 years revenue at Resmed Inc grew +11.7 % a year. The price currently implies +12.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Resmed Inc (RMD) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Resmed Inc (+12.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Resmed Inc (RMD)?
The free-cash-flow yield on the price is 3.52 %: that much free cash flow Resmed Inc produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Resmed Inc (RMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Resmed Inc it is A$35.09 per share (as of Sep 17, 2026), against a price of A$31.87. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Resmed Inc stock overvalued or undervalued in 2026?
As of Sep 17, 2026, RMD trades below its calculated fair value: price A$31.87, fair value A$35.09, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RMD?
No. The price is what the market pays today (A$31.87); the fair value is what the company's own numbers justify (A$35.09). For Resmed Inc the two are A$3.22 per share apart. That gap is exactly why we show both numbers side by side.
How much is Resmed Inc worth?
The market values Resmed Inc at about A$47.0B (market capitalisation, as of Sep 17, 2026). Per share that is A$31.87; our models calculate a fair value of A$35.09 per share.
What do the bullish and bearish scenarios say about RMD?
Our models span a range for Resmed Inc: cautious scenario A$24.56, base A$35.09, optimistic A$74.73 per share (as of Sep 17, 2026, price A$31.87). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of RMD?
Resmed Inc trades at a price-to-earnings ratio of 22.0 (as of Sep 17, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of A$35.09 is built from several models across several years. Other multiples: PEG 1.2, P/B 4.9, P/S 5.2, EV/EBITDA 13.4.
What is the PEG ratio of RMD?
The PEG ratio of Resmed Inc is 1.16 (P/E divided by earnings growth, as of Sep 17, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Resmed Inc (RMD)?
Balance-sheet figures for Resmed Inc (as of Sep 17, 2026): return on equity 25.3%, debt of 0.11 per unit of equity. They feed the Quality Score of 77/100, which measures business quality independently of the share price.
How far is RMD from its 52-week high?
Resmed Inc trades at A$31.87, about 29% below its 52-week high of A$44.92 and 25% above the low of A$25.50 (as of Sep 17, 2026). Distance from the high says nothing about value: that is what the fair value of A$35.09 is for.
Which stocks are comparable to Resmed Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Resmed Inc stock attractive at the current price?
The data as of Sep 17, 2026: price A$31.87, calculated fair value A$35.09 (+10%), Quality Score 77/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RMD calculated?
We run Resmed Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$35.09, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Resmed Inc currently trades 10 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Resmed Inc (RMD)?
The closing price on Sep 18, 2026 was A$31.87. Our model-based fair value is A$35.09, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Resmed Inc right now?
The model range is unusually wide (A$24.56 to A$74.73). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Resmed Inc (RMD) come from?
Earnings per share at Resmed Inc grew +13.2 % a year from 2014 to 2025. Broken into its drivers: revenue per share +11.6 %, EBIT margin +2.3 %, tax rate +0.2 %, residual (interest, one-offs) −1.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Resmed Inc

How large is the market capitalisation of Resmed Inc (RMD)?
The market capitalisation of Resmed Inc is A$47.0B (≈ $33.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Resmed Inc (RMD)?
The price-to-sales ratio of Resmed Inc is 5.98 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Resmed Inc (RMD)?
Earnings per share at Resmed Inc are A$1.45 (price ÷ EPS = P/E 22.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Resmed Inc (RMD)?
The dividend yield of Resmed Inc is 1.1% (payout 23.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Resmed Inc (RMD)?
The net margin of Resmed Inc is 27.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Resmed Inc (RMD)?
The return on equity (ROE) of Resmed Inc is 25.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Resmed Inc (RMD)?
On an EBIT basis the return on assets of Resmed Inc is 19.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Resmed Inc (RMD)?
The operating margin of Resmed Inc is 35.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Resmed Inc (RMD)?
Revenue at Resmed Inc is growing +10.8% versus a year earlier (3y avg +12.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Resmed Inc (RMD)?
Earnings per share at Resmed Inc are growing +10.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Resmed Inc (RMD) hold?
Resmed Inc holds more cash than debt, A$358M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Resmed Inc in the live analysis

One click puts Resmed Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.